D. Verhelle, L. Corral, K. Wong, J. Mueller, L. Moutouh-de-parseval et al., Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells, Cancer Research, vol.67, issue.2, pp.746-755, 2007.
DOI : 10.1158/0008-5472.CAN-06-2317
URL : http://cancerres.aacrjournals.org/content/canres/67/2/746.full.pdf

A. Gandhi, J. Kang, L. Capone, A. Parton, L. Wu et al., Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function, Current Cancer Drug Targets, vol.999, issue.999, pp.155-167, 2010.
DOI : 10.2174/1568210200887980096

B. Neuber, I. Herth, C. Tolliver, S. Schoenland, U. Hegenbart et al., Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma, The Journal of Immunology, vol.187, issue.2, pp.1047-1056, 2011.
DOI : 10.4049/jimmunol.1002460
URL : http://www.jimmunol.org/content/jimmunol/187/2/1047.full.pdf

K. Noonan, L. Rudraraju, A. Ferguson, A. Emerling, M. Pasetti et al., Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses, Clinical Cancer Research, vol.18, issue.5, pp.1426-1434, 2012.
DOI : 10.1158/1078-0432.CCR-11-1221
URL : http://clincancerres.aacrjournals.org/content/clincanres/18/5/1426.full.pdf

M. Attal, V. Lauwers-cances, G. Marit, D. Caillot, P. Moreau et al., Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.366, issue.19, pp.1782-1791, 2012.
DOI : 10.1056/NEJMoa1114138
URL : https://hal.archives-ouvertes.fr/hal-00852275

P. Mccarthy, K. Owzar, C. Hofmeister, D. Hurd, H. Hassoun et al., Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma, New England Journal of Medicine, vol.366, issue.19, pp.1770-1781, 2012.
DOI : 10.1056/NEJMoa1114083

M. Roussel, V. Lauwers-cances, N. Robillard, C. Hulin, X. Leleu et al., Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du My??lome, Journal of Clinical Oncology, vol.32, issue.25, pp.2712-2717, 2014.
DOI : 10.1200/JCO.2013.54.8164

K. Luptakova, J. Rosenblatt, B. Glotzbecker, H. Mills, D. Stroopinsky et al., Lenalidomide enhances anti-myeloma cellular immunity, Cancer Immunology, Immunotherapy, vol.181, issue.1, pp.39-49, 2013.
DOI : 10.4049/jimmunol.181.1.808
URL : http://europepmc.org/articles/pmc4098790?pdf=render

F. Davies, N. Raje, T. Hideshima, S. Lentzsch, G. Young et al., Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma, Blood, vol.98, issue.1, pp.210-216, 2001.
DOI : 10.1182/blood.V98.1.210
URL : http://www.bloodjournal.org/content/bloodjournal/98/1/210.full.pdf

D. Keersmaecker, B. Fostier, K. Corthals, J. Wilgenhof, S. Heirman et al., Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation, Cancer Immunology, Immunotherapy, vol.121, issue.10, pp.1023-1036, 2014.
DOI : 10.1182/blood-2012-06-435503

O. Haabeth, K. Lorvik, C. Hammarstrom, I. Donaldson, G. Haraldsen et al., Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer, Nature Communications, vol.65, issue.1, p.240, 2011.
DOI : 10.1093/jnci/80.17.1393
URL : http://www.nature.com/articles/ncomms1239.pdf

M. Ahearne, S. Willimott, L. Pinon, D. Kennedy, F. Miall et al., Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia, British Journal of Haematology, vol.207, issue.3, pp.360-370, 2013.
DOI : 10.1084/jem.20091777

E. Menoret, S. Maiga, G. Descamps, C. Pellat-deceunynck, C. Fraslon et al., IL-21 Stimulates Human Myeloma Cell Growth through an Autocrine IGF-1 Loop, The Journal of Immunology, vol.181, issue.10, pp.6837-6842, 2008.
DOI : 10.4049/jimmunol.181.10.6837
URL : http://www.jimmunol.org/content/jimmunol/181/10/6837.full.pdf

L. Wu, M. Adams, T. Carter, R. Chen, G. Muller et al., Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells, Clinical Cancer Research, vol.14, issue.14, pp.4650-4657, 2008.
DOI : 10.1158/1078-0432.CCR-07-4405
URL : http://clincancerres.aacrjournals.org/content/clincanres/14/14/4650.full.pdf

, Supplementary Information accompanies this paper on the Leukemia website